Abstract: This invention enables synthesis of proteins that were difficult to synthesize via a conventional cell-free protein synthesis system and increases the amount of proteins synthesized. Cell-free protein synthesis is carried out in a solution for cell-free protein synthesis containing a certain compound, such as trimethylglycine, L-carnitine, or sarcosine.
Abstract: The invention relates to novel compounds, processes for their preparation and their use in protecting biological materials from radiation damage (radioprotection).
Type:
Grant
Filed:
April 6, 2011
Date of Patent:
April 7, 2015
Assignee:
Peter MacCallum Cancer Institute
Inventors:
Roger Francis Martin, Jonathan White, Pavel Lobachevsky, David Winkler, Colin Skene, Sebastian Marcuccio
Abstract: The present invention relates to the cosmetic use, by the oral route, of a combination of lycopene, of vitamin C, of vitamin E and of at least one polyphenol compound derived from pine bark as active ingredient intended for maintaining and/or restoring the biomechanical properties of keratinous materials, and notably of the skin.
Type:
Grant
Filed:
December 3, 2009
Date of Patent:
April 7, 2015
Assignee:
Laboratories Inneov SNC
Inventors:
Patricia Manissier, Christiane Montastier, Antoine Piccirilli
Abstract: Compounds of structure (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and A are as defined herein are disclosed. Such compounds have enhanced water solubility and have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Enantioselective methods for preparation of compounds of structure (I), compositions comprising a compound of structure (I) in combination with a pharmaceutically acceptable carrier or diluents and methods of SHIP1 modulation by administration of such compounds to an animal in need thereof are also disclosed.
Type:
Grant
Filed:
August 22, 2011
Date of Patent:
April 7, 2015
Assignee:
The University of British Columbia
Inventors:
Xiaoxia Wang, Labros George Meimetis, Matthew Bruce Nodwell, Raymond Andersen
Abstract: The invention encompasses compounds having formula I or II and the compositions and methods using these compounds in the treatment of conditions in which inhibition of PKC and PKD is therapeutically useful.
Type:
Grant
Filed:
July 17, 2008
Date of Patent:
March 31, 2015
Assignee:
Rigel Pharmaceuticals, Inc.
Inventors:
Rajinder Singh, Hui Li, Haoran Zhao, Donald Payan, Rao Kolluri, Kin Tso, John Ramphal, Shihai Gu
Abstract: The present invention provides a compound of formula (A): as described herein, and pharmaceutically acceptable salts, enantiomers, rotamers, tautomers, or racemates thereof. Also provided are methods of treating a disease or condition mediated by PIM kinase using the compounds of Formula I, and pharmaceutical compositions comprising such compounds.
Type:
Grant
Filed:
May 20, 2013
Date of Patent:
March 24, 2015
Assignee:
Novartis AG
Inventors:
Matthew Burger, Joseph E. Drumm, III, Gisele Nishiguchi, Alice Rico, Robert Lowell Simmons, Benjamin Taft, Huw Tanner
Abstract: The present invention is directed to a rhenium complex of general Formula (I) or a pharmaceutically acceptable salt or solvate thereof, wherein X is Se; Y is NH, O or S or is a methylene group; Z is halogen; m=0, 1, or 2 and p=0, 1, or 2, provided that m and p are both different from zero when Y is NH, O or S; n=3; R? is a phenyl group or a group of general Formula —(CH2)q—COOH wherein q=1 or 2, a pharmaceutical composition comprising a therapeutically effective amount of at least one of such rhenium complex where X is additionally S or Te, a method for preparing said rhenium complex and a method for treating a proliferative growth related-disorder using a therapeutically effective amount of at least one of said rhenium complex where X is additionally S or Te. Also claimed is the use of compounds of formula (II) in the preparation of compounds of formula (I).
Type:
Grant
Filed:
June 1, 2011
Date of Patent:
March 24, 2015
Assignees:
Societe de Coordination de Recherches Therapeutiques, Universite Paris-Sud 11, Centre National de la Recherche Scientifique
Inventors:
Philippe Collery, Jean D'Angelo, Georges Morgant
Abstract: Disclosed are compounds, compositions and methods for treating metabolic diseases, including obesity and diabetes, and for reducing weight gain. Such compounds are represented by formula (I) as follows: wherein Y and Z are defined herein.
Type:
Grant
Filed:
September 27, 2012
Date of Patent:
March 24, 2015
Assignee:
Janssen Pharmaceutica NV
Inventors:
Margery Connelly, Christopher M. Flores, Mark J. Macielag
Abstract: Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
Type:
Grant
Filed:
August 4, 2014
Date of Patent:
March 24, 2015
Assignee:
Adamas Pharmaceuticals, Inc.
Inventors:
Gregory T. Went, Timothy J. Fultz, Seth Porter, Laurence R. Meyerson, Timothy S. Burkoth
Abstract: A cryogel-forming vinyl alcohol co-polymer is operable to form a cryogel, i.e., a hydrogel formed by crytropic gelation, in an aqueous solution at a concentration of less than about 10% by weight, in the absence of a chemical cross-linking agent and in the absence of an emulsifier. In one embodiment, a vinyl alcohol co-polymer cryogel comprises at least about 75% by weight water and a vinyl alcohol co-polymer, wherein the vinyl alcohol co-polymer is operable to form a cryogel in an aqueous solution at a concentration of less than about 10% by weight, in the absence of a chemical cross-linking agent and in the absence of an emulsifier.
Abstract: The present invention relates generally to the field of drug delivery systems for neuroactive steroid anaesthetic agents. More particularly, anaesthetic and sedative formulations are provided in the form of host/guest preparations comprising one or more neuroactive steroid anaesthetics and a cyclodextrin. Particular cyclodextrins contemplated include sulfoalkyl ether cyclodextrins and modified forms thereof.
Type:
Grant
Filed:
November 1, 2013
Date of Patent:
March 10, 2015
Assignee:
Drawbridge Pharmaceuticals Pty Ltd
Inventors:
Juliet Marguerite Goodchild, Colin Stanley Goodchild, Benjamin James Boyd
Abstract: A composition for topical application to a part of the body comprises a vasodilator, for example glyceryl trinitrate, as active ingredient dissolved in a blend of volatile and non-volatile solvents of different solvating capacities for the vasodilator. The vasoldator is present in the composition at a concentration at or slightly below saturation, whereby evaporation of the volatile solvent in use will maintain the vasodilator at saturated or super-saturated concentrations in the residue, whereby the vasodilator will become saturated or supersaturated in the solvent remaining and, as the active ingredient passes through the skin and is absorbed in the bloodstream, and thus becomes depleted in the residual composition, continuing evaporation of volatile solvent will maintain the active ingredient substantially at saturation or supersaturation level in the residual composition throughout the major part of the absorption phase, thereby maximising absorption levels but at a moderate dosage level.
Type:
Grant
Filed:
August 8, 2005
Date of Patent:
February 10, 2015
Assignee:
Futura Medical Developments Limited Surrey Technology Centre
Abstract: The present invention provides methods and formulations for reducing or inhibiting increase in the concentration of microbes in a water-based fluid. The methods and formulations of the present invention use glutaraldehyde and a hydroxymethyl-substituted phosphorus compound selected from the group consisting of tetrakis(hydroxymethyl)phosphonium salts, C1-C3 alkyl- and alkenyltris(hydroxymethyl)phosphonium salts and tris(hydroxymethyl)phosphine, in a ratio of hydroxymethyl-substituted phosphorus compound to glutaraldehyde in the range of about 2:1 to about 7:1, or about 3.5:1 to about 7.5:1. The methods and formulations of the present invention can be useful in treating water contaminated with aerobic or anaerobic bacteria in oilfield and other industrial applications.
Abstract: Methods of treating or suppressing mitochondrial diseases, such as Friedreich's ataxia (FRDA), Leber's Hereditary Optic Neuropathy (LHON), mitochondrial myopathy, encephalopathy, lactacidosis, stroke (MELAS), Kearns-Sayre Syndrome (KSS), are disclosed, as well as compounds useful in the methods of the invention, such as 2-(3-hydroxy-3-methyl-butyl)-6-(het)aryl-p-quinone or as 2-(3-hydroxy-3-methylbutyl)-3-(het)aryl-p-quinone derivatives. Energy biomarkers useful in assessing the metabolic state of a subject and the efficacy of treatment are also disclosed. Methods of modulating, normalizing, or enhancing energy biomarkers, as well as compounds useful for such methods, are also disclosed.
Abstract: Provided are a marker for determining sensitivity to an anticancer agent capable of distinguishing a therapeutic response of an individual patient and a novel means for a cancer therapy using the marker. The marker for determining sensitivity to an anticancer agent contains a substance in a metabolic pathway in which L-phenylalanine and/or N,N-dimethyl glycine are/is involved.
Abstract: The invention relates to lipoic acid acylated salicylate derivatives; compositions comprising an effective amount of a lipoic acid acylated salicylate derivative; and methods for treating or preventing an metabolic disease comprising the administration of an effective amount of a lipoic acid acylated salicylate derivative.
Type:
Grant
Filed:
October 5, 2010
Date of Patent:
February 3, 2015
Assignee:
Catabasis Pharmaceuticals, Inc.
Inventors:
Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Chi B. Vu
Abstract: To provide an anthranilamide formulation compound for improving pest controlling effects. A solid composition for pest control which comprises an amorphous anthranilamide compound or its salt as a pesticidal active ingredient, a nonionic surfactant and/or an anionic surfactant and a mineral carrier.
Abstract: The present invention relates to crystalline form I of Febuxostat as well as to pharmaceutical compositions comprising crystalline form I as an active pharmaceutical ingredient. Furthermore the present invention relates to a further polymorphic form of Febuxostat designated as form II and to a novel solvate of Febuxostat. The present invention also relates to methods of making crystalline form I, form II and the novel solvate of Febuxostat.
Type:
Grant
Filed:
June 24, 2011
Date of Patent:
February 3, 2015
Assignee:
Sandoz AG
Inventors:
Andreas Hotter, Ulrich Griesser, Verena Adamer, Christoph Langes
Abstract: The invention provides compounds and pharmaceutically acceptable salts and esters and compositions thereof, for treating viral infections. The compounds and compositions are useful for treating Pneumovirinae virus infection including Human respiratory syncytial virus infections.
Type:
Grant
Filed:
December 20, 2012
Date of Patent:
February 3, 2015
Assignee:
Gilead Sciences, Inc.
Inventors:
Constantine G. Boojamra, Hon Chung Hui, Petr Jansa, Richard L. Mackman, Jay P. Parrish, Michael Sangi, Dustin Siegel, David Sperandio, Hai Yang